The 10-year cumulative CBC, OC, and nonbreast/ovarian cancer risk estimates are applicable to carriers and tested noncarriers ascertained through clinical genetics centers, and the CBC risk estimates for BRCA1/BRCA2 PV carriers were broadly consistent with a large previous study with similar ascertainment criteria.8 However, they would overestimate the risks in BRCA1/BRCA2 PV carriers unselected for cancer FH, emphasizing the importance of integrating FH in the counseling and risk estimation process.20 The gene discussed is BRCA2; the disease is ovarian carcinoma.